Abstract: Salts of ionic dyes with compounds which contain at least one ammonium, cycloammonium or immonium group and at least one aliphatic, cycloaliphatic or carbonyl radical-substituted aromatic group or containing a piperazine or piperidine group or a heteroaromatic group selected from those of the triazine, pyrimidine, quinazoline, quinoxaline, phthalazine or phthalimidine series or which contain at least two carboxylic acid groups, at least one amino group and at least one carboxylic acid group or at least one sulfonic acid group and one aliphatic, cycloaliphatic, monocyclic aromatic or heteroaromatic group are useful for dyeing synthetic materials, particularly synthetic polyamides in the mass. The obtained dyeings have exceptionally good wet fastness.

Abstract: The invention concerns pharmaceutical compositions comprising clozapine and a radical scavenger.

Abstract: Pigments of the formulaA.sub.m --F--R.sub.n,whereineach A is a monobasic or dibasic acid group,F is the residue of a dye,each R is a group containing an aliphatic-, cycloaliphatic- or aliphatic-heterocyclic-bound imino or amino nitrogen atom,m is 1 or 2, andn is equal to m when A is a monobasic acid group and equal to 2m when A is a dibasic acid group.

Abstract: A screening method for detecting the vulnerability of patients on clozapine therapy to developing agranulocytosis which comprises establishing the concentration of N-desmethylclozapine in the blood or bone marrow of said patient. In addition, a method of determining patient sensitivity to N-desmethylclozapine is provided which comprises collecting heparinized blood and assaying it for stem cell sensitivity to N-desmethylclozapine.

Abstract: A process for synthesizing compounds of the formula ##STR1## utilizing, as intermediates, oxalyl chloride or bromide and compounds of the formulae R.sub.1 R.sub.2 N--CHO and CH.sub.2 .dbd.CH--O--R.sub.10 are processes for synthesizing compounds of the formula ##STR2## utilizing, as intermediates, compounds of Formula I wherein R.sub.1 is phenyl or substituted phenyl or intermediates in the synthesis of the compounds of formula I which intermediates have the formula ##STR3## wherein R.sub.1 is C.sub.1-3 alkyl, phenyl or phenyl substituted by 1 to 3 substituents each of which is independently C.sub.1-3 alkyl, C.sub.1-3 alkoxy, fluoro, chloro, bromo or nitro (maximum of two nitro groups),R.sub.2 is C.sub.1-3 alkyl,R.sub.10 is C.sub.1-6 alkyl,X.sup..crclbar. is chloride or bromide, andR.sub.3 -R.sub.6 are as defined in the specification.

Abstract: The invention discloses certain heterocyclic, thioether, keto-ester and alkyl phospholipids, e.g., heterocyclic phospholipids having the formula ##STR1## where R is n-C.sub.14 -C.sub.20 alkyl or O-n-C.sub.14 -C.sub.20 alkyl; each R.sub.1 is methyl or ethyl; n is 2-6; and X is --CH.sub.2 --m, where m is 2-4, CH.sub.2 CH.sub.2 O or CH.sub.2 CH.sub.2 S, or a corresponding hydrate thereof, which compounds are useful in treating multiple sclerosis.

Abstract: Hydroxy-substituted [(D)Ser].sup.8 -Ciclosporin derivatives, particularly [O-(2-hydroxyethyl)(D)Ser].sup.8 -Ciclosporin, have advantageous pharmacological properties and are useful as immunosuppressants, for example in the treatment of transplant rejection and autoimmune diseases.

Abstract: Compounds of formula I ##STR1## wherein R.sub.1 and R.sub.2 are the same or different and each represent hydrogen, alkyl, alkenyl, cycloalkyl, aryl or aralkyl are produced by a new environmentally acceptable process.

Abstract: 1:2 metal complexes of the formula ##STR1## wherein each of R.sub.1 and R.sub.3 is independently hydrogen or nitro, with the proviso that when a ring has two nitro groups, they are meta to each other,each of R.sub.2 and R.sub.4 is independently hydrogen, chloro or --SO.sub.3 M,each of R.sub.5 and R.sub.6 is independently hydrogen, --COR.sub.7, --CONHR.sub.8 or --SO.sub.2 R.sub.9,wherein R.sub.7 is C.sub.1-6 alkyl, C.sub.1-6 alkoxy, phenyl(C.sub.1-4 -alkyl) or phenyl(C.sub.1-4 -alkyl) the phenyl group of which is substituted by 1 or 2 substituents selected from halo, C.sub.1-4 -alkyl, C.sub.1-4 alkoxy, nitro, amino, --COOM, --SO.sub.3 M and acetamido,R.sub.8 is hydrogen, C.sub.1-6 alkyl; phenyl; phenyl substituted by 1 or 2 substituents selected from halo, C.sub.1-4 -alkyl, C.sub.1-4 alkoxy, nitro, amino, --COOM, --SO.sub.3 M and acetamido; naphthyl or naphthyl monosubstituted by chloro, amino, phenylamino, acetamido, benzamido or --SO.sub.3 M, andR.sub.9 is C.sub.

Abstract: A compound of formula I ##STR1## wherein R.sub.1 is C.sub.1-4 alkyl, C.sub.3-4 alkenyl or (C.sub.3-5 cycloalkyl)-methyl, R.sub.2 is C.sub.1-4 alkyl, [hydroxy- or (C.sub.1-4 alkoxy)-substituted C.sub.1-3 alkyl]-methyl, (C.sub.3-5 cycloalkyl)-methyl, tetrahydrofuran 2-yl-methyl or 1,3-dioxolan-2-yl-methyl, R.sub.3 and R.sub.4 are each hydrogen, hydroxymethyl, methoxymethyl or N,N-dimethylcarbamoyloxymethyl, R.sub.5 is hydroxy or methoxy, R.sub.6 is hydrogen, hydroxy, methoxy or halogen and R.sub.7 is in the 2- or 3-position and is hydroxy, methoxy or halogen, or together with R.sub.5 is 3,4-methylendioxy, or together with R.sub.6 is 2,3-methylenedioxy and their physiologically-hydrolysable and -acceptable esters are useful in the treatment (symptomatic and prophylactic) of obstructive or inflammatory airways disease, in particular asthma, and disease characterised by or having an aetiology comprising morbid eosinophil accumulation or activation, e.g. hypereosinophilia.

Abstract: The invention relates to a novel stable form of cephradine, processes for its production and intermediates used therein.

Abstract: The invention provides use of a 5HT-3 antagonist in the manufacture of a medicament suitable for the prevention or reduction of dependence on a dependence-inducing agent.

Abstract: 3,7-disubstituted indole derivatives of formula I ##STR1## wherein R.sub.1, R.sub.2, n, X, Y and Z are as defined in the description are useful for the treatment of psychiatric disorders.

Abstract: The invention relates to the compound of formula I ##STR1## in free base form or in acid addition salt form its preparation and use as a medicament for glaucoma, depression, Morbus Parkinsonism or cocaine abuse.

Abstract: A nutritionally complete feeding composition contains soluble fiber, especially hydrolyzed guar gum or pectin. This composition provides nourishment to colon cells, preventing bacterial sepsis and also preventing diarrhea.

Abstract: Use of calcium antagonists of formula I ##STR1## wherein the substituents have various significances in the treatment of conditions related directly or indirectly to ionized calcium levels in the blood and combinations of calcium antagonists, e.g. of formula I, with calcitonins.

Abstract: Method for placing a guide wire through a gastrostomy tube which has a plug through which only the guide wire can pass in slidable communication. The plug prevents air from escaping from the stomach, thus, preventing the collapse of the stomach during the guide wire placement. The plug may comprise a substantially cylindrical member having a longitudinal bore for receiving the guide wire in slidable communication.

Abstract: Nutritional supplements and methods of use of the supplements to maximally stimulate gallbladder contraction in patients undergoing rapid weight loss, to prevent the build up of bilary sludge and/or gallstones.

Abstract: The invention provides immunostimulatory compositions comprising an aggregate immunostimulatory amount ofa) a compound associated with the synthesis of polyamines,b) a nucleobase source,c) omega-3 polyunsaturated fatty acids, andd) omega-6 polyunsaturated fatty acidsthe use of such compositions and their manufacture.

Abstract: A process for preparing the (R) stereoisomer of 2,2-bis(hydroxmethyl)-tetrahydrofuran monobutyrate comprising subjecting the dibutyric ester of the 2,2-bis(hydroxymethyl)-tetrahydrofuran to enzymatic hydrolysis. The invention also relates to the novel (R) stereoisomer prepared by the instant process and to its more stable forms. In addition, the invention relates to the use of the (R) stereoisomer in preparing stereoisomers of pharmacologically active compounds and to certain specific stereoisomers produced thereby.